Nesuparib clinical trials
Also written JPI-547.
How each study uses nesuparib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the nesuparib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Related medicines
As reviewed, each with the page that says it.
- One of PARP inhibitors source
Studies
Open first, then newest update. How each study uses nesuparib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial CancerRecruitingPhase 2Yonsei UniversityNCT06502743Written as Nesuparib
- Food and Ethnicity Effects on Pharmacokinetics and Safety of JPI-547 in Healthy Male ParticipantsNot yet recruitingPhase 1Onconic Therapeutics Inc.NCT07570186Written as JPI-547
- To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric CancerNot yet recruitingPhase 1/2Onconic Therapeutics Inc.NCT07364422Written as JPI-547
- A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP InhibitorActive, not recruitingPhase 2Onconic Therapeutics Inc.NCT05475184Written as JPI-547
- A Study of NOV140201 (JPI-547) in Subject With Advanced Solid TumorsCompletedPhase 1Onconic Therapeutics Inc.NCT04335604Written as JPI-547
Given beside what is tested · 2 — nesuparib is usual care or a partner of the new treatment
- Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic CancerRecruitingPhase 1/2Onconic Therapeutics Inc.NCT05257993Written as JPI-547
- To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian CancerNot yet recruitingPhase 2Onconic Therapeutics Inc.NCT07370818Written as JPI-547
Codes
What other systems call nesuparib · ClinicalTrials.gg INT018092
- UNII (FDA) U6N7333GDWNESUPARIBOne source FDA
- NCI Thesaurus C187049NesuparibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | U6N7333GDW | NESUPARIB | One source FDA |
| NCI Thesaurus | C187049 | Nesuparib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.